What did @therealistic.dietitian actually say?
The creator's core argument is that injectable peptides trending on TikTok, including BPC-157, TB-500, and CJC-1295, are "research chemicals" that are "completely unregulated illegal substances, at least in Australia." She draws a clear line between these experimental compounds and regulated peptide-based medications like GLP-1 receptor agonists. Her framing is cautionary, not dismissive of peptides altogether.
She also flags practical unknowns: purity of the product, correct dosing, and long-term safety data. And she correctly notes that injection itself carries infection and immune reaction risks regardless of what's in the vial. For a short TikTok aimed at a general audience, the structural argument is sound. The details, though, deserve a closer look.
Does the science back this up?
Mostly, yes. The human evidence base for most of these peptides is genuinely thin. BPC-157, probably the most hyped compound on this list, has a substantial body of rodent data showing effects on tendon healing and gut mucosa, but peer-reviewed human clinical trials are nearly nonexistent as of 2024. TB-500, a synthetic fragment of thymosin beta-4, is in a similar position: animal data, no robust human RCTs.
CJC-1295 and ipamorelin have slightly more human pharmacokinetic data, largely because growth hormone secretagogues attracted pharma interest before the FDA tightened compounding rules in 2023. A study by Ionescu and Frohman (2004, Growth Hormone and IGF Research) confirmed CJC-1295 elevates GH and IGF-1 in healthy adults, but that tells us about mechanism, not long-term safety. The creator's point about unknown vial contents is also backed by documented contamination and mislabeling issues in gray-market peptide supply chains, flagged in a 2022 FDA import alert covering numerous "research-use-only" suppliers.
What did they get wrong (or right)?
She gets the big picture right but oversimplifies the legal framing. Calling these substances "illegal" is accurate for Australia under the Therapeutic Goods Act, where unapproved therapeutic goods cannot be legally imported or injected. But the legal picture varies significantly by country. In the United States, for example, many of these peptides existed in a gray zone: technically legal to sell as research chemicals, not for human use, until the FDA and compounding pharmacy crackdowns between 2021 and 2023 narrowed that space considerably.
She also slightly conflates "no human evidence" with "no evidence." That is not quite right. There is preclinical evidence, and some peptides like BPC-157 have been studied in small human case series, even if those don't meet the bar for clinical approval. The distinction matters because it affects how a curious patient should weigh risk, not just whether something has a regulatory stamp. That said, preclinical data does not predict human safety or efficacy, and the creator is right to treat absence of human trials as a serious red flag.
Her GLP-1 comparison is accurate and useful. Semaglutide and tirzepatide are peptide-based, FDA and TGA-approved, with extensive phase 3 trial data. That comparison illustrates what regulated peptide medicine actually looks like.
What should you actually know?
The regulatory landscape for these compounds shifted meaningfully in recent years. The FDA placed BPC-157 and TB-500 on a list of bulk drug substances that cannot be used in compounding in 2023, meaning even compounding pharmacies in the US can no longer legally produce them for patient use. That is a harder legal line than existed two years ago.
Contamination risk is real and documented. A 2021 analysis published in Drug Testing and Analysis found that a significant proportion of gray-market peptide products tested did not match their labeled contents, with some containing no active compound at all and others showing bacterial endotoxin contamination. Injecting an unknown substance carries infection risk, immune reaction risk, and the risk of simply not knowing what you're actually putting into your body.
If you are interested in peptide-based therapies for legitimate health goals, the appropriate path is a licensed telehealth or in-person provider who can prescribe FDA-approved or TGA-approved compounds with documented safety profiles. The creator's call to consult a doctor before injecting trending compounds is, bluntly, correct.